Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02242942 · OUTCOME

Serum Concentrations of Obinutuzumab

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia · Source last updated 2025-11-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
μg/mL
Interval / dispersion
Standard Deviation
Time frame
Pre-obinutuzumab infusion (0 hour) and end of obinutuzumab infusion on Day 1 Cycle 4

Analysis population: Analysis population consisted of subjects from whom one or more serum samples were collected and who had received at least one dose of obinutuzumab and one dose of 400 mg venetoclax. Pre-dose and post-dose data may not come from the same participants. Total number analyzed is therefore higher than the number analyzed for each time point.

Groups in this outcome

Obinutuzumab + Venetoclax

Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Obinutuzumab + Venetoclax184

Reported measurements

Pre-Dose

Analysis denominator · Participants

GroupSource count
Obinutuzumab + Venetoclax133
Values in μg/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Obinutuzumab + Venetoclax258140Not reportedNot reportedNot reported
4 hours Post-Dose

Analysis denominator · Participants

GroupSource count
Obinutuzumab + Venetoclax133
Values in μg/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Obinutuzumab + Venetoclax568187Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        140
        value
        258
    denoms
    1. counts
      1. group Id
        OG000
        value
        133
      units
      Participants
    title
    Pre-Dose
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        187
        value
        568
    denoms
    1. counts
      1. group Id
        OG000
        value
        133
      units
      Participants
    title
    4 hours Post-Dose
denoms
  1. counts
    1. group Id
      OG000
      value
      184
    units
    Participants
dispersion Type
Standard Deviation
groups
  1. description
    Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.
    id
    OG000
    title
    Obinutuzumab + Venetoclax
param Type
MEAN
population Description
Analysis population consisted of subjects from whom one or more serum samples were collected and who had received at least one dose of obinutuzumab and one dose of 400 mg venetoclax. Pre-dose and post-dose data may not come from the same participants. Total number analyzed is therefore higher than the number analyzed for each time point.
reporting Status
POSTED
time Frame
Pre-obinutuzumab infusion (0 hour) and end of obinutuzumab infusion on Day 1 Cycle 4
title
Serum Concentrations of Obinutuzumab
type
SECONDARY
unit Of Measure
μg/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice